180 Life Sciences’ (ATNF) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of 180 Life Sciences (NASDAQ:ATNF) in a report published on Saturday,Weiss Ratings reports.

180 Life Sciences Trading Down 5.0 %

NASDAQ ATNF opened at $1.33 on Friday. 180 Life Sciences has a 12 month low of $1.16 and a 12 month high of $17.75. The company’s 50 day simple moving average is $1.86 and its 200 day simple moving average is $2.19.

180 Life Sciences Company Profile

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.